Edgewise Therapeutics, Inc. (EWTX): Free Cash Flow
-$144.07M
Year ended 2025-12-31
-$158.83M
Trailing 12 months to 2026-06-30
| Period ended | Free Cash Flow | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$144.07M | n/m | 2026-02-26, From 2025-01-01 |
| 2024-12-31 | -$110.34M | n/m | 2026-02-26, From 2024-01-01 |
| 2023-12-31 | -$97.69M | n/m | 2026-02-26, From 2023-01-01 |
| 2022-12-31 | -$58.18M | n/m | 2024-02-22, From 2022-01-01 |
| 2021-12-31 | -$34.17M | n/m | 2023-02-23, From 2021-01-01 |
| 2020-12-31 | -$14.84M | n/a | 2022-02-24, From 2020-01-01 |
Free Cash Flow at similar companies
| Company | Year ended | Free Cash Flow | Change YoY |
|---|---|---|---|
| Edgewise Therapeutics, Inc. (EWTX) | 2025-12-31 | -$144.07M | n/m |
| Standard Biotools Inc. (LAB) | 2025-12-31 | -$82.65M | n/m |
| Geron Corp (GERN) | 2024-12-31 | -$219.30M | n/m |
| Olema Pharmaceuticals, Inc. (OLMA) | 2024-12-31 | -$104.51M | n/a |
| Syndax Pharmaceuticals Inc (SNDX) | 2025-12-31 | -$323.17M | n/m |
| Rapport Therapeutics, Inc. (RAPP) | 2025-12-31 | -$88.09M | n/m |
| Septerna, Inc. (SEPN) | 2025-12-31 | $109.67M | n/m |
| Organogenesis Holdings Inc. (ORGO) | 2025-12-31 | -$24.46M | n/m |
| Ardelyx, Inc. (ARDX) | 2025-12-31 | -$43.98M | n/m |
Compare EWTX, LAB, GERN, OLMA side by side · Screen every company in Pharmaceutical Preparations ↗